PURPOSE: There are no published reports on the optimal management and survival rates of children with Wilms tumor (WT) and peritoneal implants (PIs). METHODS AND MATERIALS: Among favorable histology WT patients enrolled in the National Wilms Tumor Study (NWTS)-4 and NWTS-5, 57 children had PIs at the time of nephrectomy. The median age was 3 years 5 months (range, 3 months to 14 years). The majority of children (42 of 57 [74%)] had Stage III tumors; 15 had Stage IV disease. All patients received multimodality therapy. Of 56 children who underwent primary surgery, 48 (84%) had gross total resection of all tumors. All patients received 3-drug chemotherapy with vincristine, dactinomycin, and doxorubicin. Whole-abdomen radiotherapy (RT) was used in 47 patients (82%), and in 50 patients (88%) the RT dose was 10.5 Gy. RESULTS: After a median follow-up of 7.5 years, the overall abdominal and systemic tumor control rates were 97% and 93%, respectively. A comparative analysis between children with PIs and those without PIs showed no significant differences in the clinical characteristics between the two groups. The 5-year event-free survival rates with and without PIs were 90% (95% confidence interval, 78-96%) and 83% (95% confidence interval, 81-85%) respectively (p = 0.20). CONCLUSIONS: Multimodality therapy with surgery, whole-abdomen RT, and three-drug chemotherapy delivered according to the NWTS-4 and -5 protocols resulted in excellent abdominal and systemic tumor control rates. All children should be monitored in long-term surveillance programs for the early detection and management of therapy-related toxicities. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: There are no published reports on the optimal management and survival rates of children with Wilms tumor (WT) and peritoneal implants (PIs). METHODS AND MATERIALS: Among favorable histology WTpatients enrolled in the National Wilms Tumor Study (NWTS)-4 and NWTS-5, 57 children had PIs at the time of nephrectomy. The median age was 3 years 5 months (range, 3 months to 14 years). The majority of children (42 of 57 [74%)] had Stage III tumors; 15 had Stage IV disease. All patients received multimodality therapy. Of 56 children who underwent primary surgery, 48 (84%) had gross total resection of all tumors. All patients received 3-drug chemotherapy with vincristine, dactinomycin, and doxorubicin. Whole-abdomen radiotherapy (RT) was used in 47 patients (82%), and in 50 patients (88%) the RT dose was 10.5 Gy. RESULTS: After a median follow-up of 7.5 years, the overall abdominal and systemic tumor control rates were 97% and 93%, respectively. A comparative analysis between children with PIs and those without PIs showed no significant differences in the clinical characteristics between the two groups. The 5-year event-free survival rates with and without PIs were 90% (95% confidence interval, 78-96%) and 83% (95% confidence interval, 81-85%) respectively (p = 0.20). CONCLUSIONS: Multimodality therapy with surgery, whole-abdomen RT, and three-drug chemotherapy delivered according to the NWTS-4 and -5 protocols resulted in excellent abdominal and systemic tumor control rates. All children should be monitored in long-term surveillance programs for the early detection and management of therapy-related toxicities. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: G J D'Angio; A Evans; N Breslow; B Beckwith; H Bishop; V Farewell; W Goodwin; L Leape; N Palmer; L Sinks; W Sutow; M Tefft; J Wolff Journal: Cancer Date: 1981-05-01 Impact factor: 6.860
Authors: Daniel M Green; Eve M Peabody; Bin Nan; Susan Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: John A Kalapurakal; Susan Peterson; Eve M Peabody; Patrick R M Thomas; Daniel M Green; Giulio J D'angio; Norman E Breslow Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: G J D'Angio; A E Evans; N Breslow; B Beckwith; H Bishop; P Feigl; W Goodwin; L L Leape; L F Sinks; W Sutow; M Tefft; J Wolff Journal: Cancer Date: 1976-08 Impact factor: 6.860
Authors: Aliki J Taylor; David L Winter; Kathy Pritchard-Jones; Charles A Stiller; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Mike M Hawkins Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: John A Kalapurakal; Sierra M Li; Norman E Breslow; J Bruce Beckwith; Roger Macklis; Patrick R M Thomas; Guilio J D'Angio; Tae Kim; Alfred de Lorimier; Panayotis Kelalis; Steven Shochat; Michael Ritchey; Gerald Haase; Ellen Hrabovsky; H Biemann Otherson; Paul Grundy; Daniel M Green Journal: Int J Radiat Oncol Biol Phys Date: 2003-10-01 Impact factor: 7.038
Authors: Kevin X Liu; Yu-Hui Chen; David Kozono; Raymond H Mak; Patrick J Boyle; Katherine A Janeway; Elizabeth A Mullen; Karen J Marcus Journal: Adv Radiat Oncol Date: 2020-09-23